On 3 March 2005, orphan designation (EU/3/05/263) was granted by the European Commission to AOP Orphan Pharmaceuticals AG, Austria, for dimethyl sulfoxide for the treatment of severe closed traumatic brain injury.
In February 2022, the sponsor’s address was updated and the name was changed from AOP Orphan Pharmaceuticals AG to Aop Orphan Pharmaceuticals GmbH.
Treatment of severe closed traumatic brain injury
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: